The Filing Desk

Qiagen vs Bio-Techne

Qiagen QGEN · Bio-Techne TECH · Life Sciences Tools & Services

Qiagen reported revenue of $2.1 billion in fiscal 2025, 1.7 times Bio-Techne's $1.2 billion in fiscal 2026. Qiagen's revenue grew 5.7% in its latest year, and Bio-Techne's fell 0.4%. Qiagen had an operating margin of 22.3%, against 20.7% at Bio-Techne. Free cash flow was $453 million at Qiagen and $263 million at Bio-Techne. Their fiscal years end in different months (December 31 and June 30), so the periods don't line up exactly.

Side by side

QiagenBio-Techne
Latest fiscal yearFY2025, Dec 31, 2025FY2026, Jun 30, 2026
Revenue$2.1B$1.2B
Revenue growth5.7%−0.4%
Revenue growth a year, last 5 years2.2%5.5%
Gross margin62.2%65.8%
Operating margin22.3%20.7%
Net margin20.3%15.0%
Free cash flow$453M$263M
Free cash flow margin21.7%21.7%
Return on capital9.9%9.2%
Net debt to EBITDA0.8x−0.2x
Dividends and buybacks$334M$92M
Change in diluted share count−2.6%−1.7%
Last close$49.63$72.70
P/E at the last close—66.7×
Insider trades, last 12 months—sold $437,187
Piotroski F-score8 of 99 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
QiagenBio-Techne
Operating margin
Percent of revenue
QiagenBio-Techne
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
QiagenBio-Techne

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Qiagen and Bio-Techne pages.